Signal Genetics receives Investment Bank Analyst Rating Update
Investing.com - Viridian Therapeutics (NASDAQ: VRDN) reported first quarter EPS of $-1.61, $0.60 worse than the analyst estimate of $-1.01. Revenue for the quarter came in at $100K...
Viridian Therapeutics, Inc. (VRDN), a biopharmaceutical company focused on discovering and developing potential best-in-class medicines for serious and rare diseases, today...
Shares of Miragen Therapeutics, Inc. (NASDAQ:MGEN) surged 20.7% after the company reported positive data from its continuing Phase 1 trial of cobomarsen in adult t-cell...
Signal Genetics, Inc. (NASDAQ:MGEN) is a clinical-stage biopharmaceutical company that could be an interesting play for investors. That is because, not only does the stock have...
Post the 2016 debacle, the biotech space raised hopes with growing stability this year. However, the sector has been witnessing a correction since October. It has lost 10.4% so far...
Viridian Therapeutics, Inc. is a biotechnology company focused on discovering and developing medicines for serious and rare diseases. The Company is engaged in developing three product candidates, VRDN-001, VRDN-002, and VRDN-003, that is developed for intravenous (IV) or subcutaneous administration to treat patients who suffer from thyroid eye disease (TED). Its lead product candidate, VRDN-001, is a differentiated humanized monoclonal antibody targeting insulin-like growth factor-1 receptor (IGF-1R), a clinically and commercially validated target for the TED. It has initiated a Phase I/II clinical trial of VRDN-001. Its second product candidate, VRDN-002, is a distinct IGF-1R antibody that incorporates half-life extension technology, and is designed to support administration as a convenient, low volume, subcutaneous injection to treat patients who suffer from TED. VRDN-003 is an anti-IGF-1R monoclonal antibody with the same amino acid sequence as VRDN-001.
|Average||46.130 (+93.580% Upside)|
|No. of Analysts||15|